Based on the Regeneron Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Regeneron Pharmaceuticals Inc is not available over the next 12 months. Regeneron Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Regeneron Pharmaceuticals Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Regeneron Pharmaceuticals Inc’s stock price was EUR 717.60. Regeneron Pharmaceuticals Inc’s stock price has changed by -5.95% over the past week, -22.81% over the past month and -1.77% over the last year.
No recent analyst target price found for Regeneron Pharmaceuticals Inc
No recent average analyst rating found for Regeneron Pharmaceuticals Inc
Company Overview Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Read Less
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroi...Read More
Frequently Asked Questions About Regeneron Pharmaceuticals Inc (RGO:F) Stock
Stock Target Advisor's fundamental analysis for Regeneron Pharmaceuticals Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on RGO:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RGO:F's stock to indicate what its average analyst target is.
RGO:F stock's Price/Earning ratio is 20.37.
Our analysis grades RGO:F stock's Price / Earning ratio at F. This means that RGO:F stock's Price/Earning ratio is above 50% of the stocks in the Biotechnology sector in the F exchange.
Based on this RGO:F may be fairly valued for its sector
The last closing price of RGO:F's stock was EUR 717.60.
The most recent market capitalization for RGO:F is EUR 84.33B.
Unfortunately we do not have enough analyst data on RGO:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Regeneron Pharmaceuticals Inc's stock.
As per our most recent records Regeneron Pharmaceuticals Inc has 14,165 Employees.
Regeneron Pharmaceuticals Inc's registered address is 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707.
You can get more information about it from Regeneron Pharmaceuticals Inc's website at https://www.regeneron.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Regeneron Pharmaceuticals Inc (RGO:F) Stock
Stock Target Advisor's fundamental analysis for Regeneron Pharmaceuticals Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on RGO:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RGO:F's stock to indicate what its average analyst target is.
RGO:F stock's Price/Earning ratio is 20.37.
Our analysis grades RGO:F stock's Price / Earning ratio at F. This means that RGO:F stock's Price/Earning ratio is above 50% of the stocks in the Biotechnology sector in the F exchange.
Based on this RGO:F may be fairly valued for its sector
The last closing price of RGO:F's stock was EUR 717.60.
The most recent market capitalization for RGO:F is EUR 84.33B.
Unfortunately we do not have enough analyst data on RGO:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Regeneron Pharmaceuticals Inc's stock.
As per our most recent records Regeneron Pharmaceuticals Inc has 14,165 Employees.
Regeneron Pharmaceuticals Inc's registered address is 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707.
You can get more information about it from Regeneron Pharmaceuticals Inc's website at https://www.regeneron.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RGO:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
